Toward a Molecular Understanding of the Interaction of Dual Specificity Phosphatases with Substrates: Insights from Structure-Based Modeling and High Throughput Screening

被引:36
作者
Bakan, Ahmet
Lazo, John S. [2 ,4 ]
Wipf, Peter [3 ,4 ]
Brummond, Kay M. [3 ,4 ]
Bahar, Ivet [1 ,4 ]
机构
[1] Univ Pittsburgh, Dept Computat Biol, Sch Med, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA
[4] Univ Pittsburgh, Drug Discovery Inst, Pittsburgh, PA 15260 USA
关键词
Dual-specificity phosphatases; computer-aided drug discovery; high throughput screening; structure-based virtual screening; molecular docking; intrinsic dynamics; focused library design;
D O I
10.2174/092986708785909003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dual-specificity phosphatases (DSPs) are important, but poorly understood, cell signaling enzymes that remove phosphate groups from tyrosine and serine/threonine residues on their substrate. Deregulation of DSPs has been implicated in cancer, obesity, diabetes, inflammation, and Alzheimer's disease. Due to their biological and biomedical significance, DSPs have increasingly become the subject of drug discovery high-throughput screening (HTS) and focused compound library development efforts. Progress in identifying selective and potent DSP inhibitors has, however, been restricted by the lack of sufficient structural data on inhibitor-bound DSPs. The shallow, almost flat, substrate binding sites in DSPs have been a major factor in hampering the rational design and the experimental development of active site inhibitors. Recent experimental and virtual HTS studies, as well as advances in molecular modeling, provide new insights into the potential mechanisms for substrate recognition and binding by this important class of enzymes. We present herein an overview of the progress, along with a brief description of applications to two types of DSPs: Cdc25 and MAP kinase phosphatase (MKP) family members. In particular, we focus on combined computational and experimental efforts for designing Cdc25B and MKP-1 inhibitors and understanding their mechanisms of interactions with their target proteins. These studies emphasize the utility of developing computational models and methods that meet the two major challenges currently faced in structure-based in silico design of lead compounds: the conformational flexibility of the target protein and the entropic contribution to the selection and stabilization of particular bound conformers.
引用
收藏
页码:2536 / 2544
页数:9
相关论文
共 87 条
[41]   Structurally unique inhibitors of human mitogen-activated protein kinase phosphatase-1 identified in a pyrrole carboxamide library [J].
Lazo, John S. ;
Skoko, John J. ;
Werner, Stefan ;
Mitasev, Branko ;
Bakan, Ahmet ;
Koizumi, Fumito ;
Yellow-Duke, Archibong ;
Bahar, Ivet ;
Brummond, Kay M. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 322 (03) :940-947
[42]   Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1 [J].
Lazo, John S. ;
Nunes, Ruth ;
Skoko, John J. ;
de Oliveira, Pierre E. Queiroz ;
Vogt, Andreas ;
Wipf, Peter .
BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (16) :5643-5650
[43]   Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. [J].
Lazo, JS ;
Nemoto, K ;
Pestell, KE ;
Cooley, K ;
Southwick, EC ;
Mitchell, DA ;
Furey, W ;
Gussio, R ;
Zaharevitz, DW ;
Joo, B ;
Wipf, P .
MOLECULAR PHARMACOLOGY, 2002, 61 (04) :720-728
[44]   Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25 [J].
Lazo, JS ;
Aslan, DC ;
Southwick, EC ;
Cooley, KA ;
Ducruet, AP ;
Joo, B ;
Vogt, A ;
Wipf, P .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (24) :4042-4049
[45]   Prediction of protein-ligand interactions. Docking and scoring: Successes and gaps [J].
Leach, Andrew R. ;
Shoichet, Brian K. ;
Peishoff, Catherine E. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (20) :5851-5855
[46]   Structural basis of docking interactions between ERK2 and MAP kinase phosphatase 3 [J].
Liu, SJ ;
Sun, JP ;
Zhou, B ;
Zhang, ZY .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (14) :5326-5331
[47]   Dual-specificity phosphatases as targets for antineoplastic agents [J].
Lyon, MA ;
Ducruet, AP ;
Wipf, P ;
Lazo, JS .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (12) :961-976
[48]   Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B [J].
Ma, ZQ ;
Chua, SS ;
DeMayo, FJ ;
Tsai, SY .
ONCOGENE, 1999, 18 (32) :4564-4576
[49]   Quantification of protein surfaces, volumes and atom-atom contacts using a constrained Voronoi procedure [J].
McConkey, BJ ;
Sobolev, V ;
Edelman, M .
BIOINFORMATICS, 2002, 18 (10) :1365-1373
[50]   Predicting absolute ligand binding free energies to a simple model site [J].
Mobley, David L. ;
Graves, Alan P. ;
Chodera, John D. ;
McReynolds, Andrea C. ;
Shoichet, Brian K. ;
Dill, Ken A. .
JOURNAL OF MOLECULAR BIOLOGY, 2007, 371 (04) :1118-1134